In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans
- PMID: 7486902
- PMCID: PMC162809
- DOI: 10.1128/AAC.39.8.1691
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans
Abstract
Amphotericin B and fluconazole are current acceptable therapies for cryptococcal meningitis; however, their effect remains suboptimal. The combination of fluconazole and flucytosine has yielded encouraging clinical results in human immunodeficiency virus patients with cryptococcal meningitis. To investigate the biological basis of this finding, we performed in vitro combination testing of fluconazole and flucytosine against 50 clinical strains of Cryptococcus neoformans var. neoformans. Synergy (fractional inhibitory concentration index of < 1.0) was observed in 62% of cases, while antagonism (fractional inhibitory concentration index of > 2.0) was not observed. For cases in which synergy was not achieved (autonomous or additive effects), the beneficial effect of the combination was still seen (i.e., there was still a decrease, although not as dramatic, in the MIC of one or both drugs when used in combination). The in vitro inhibitory action of flucytosine was greatly enhanced by the addition of fluconazole; the flucytosine MICs for Cryptococcus isolates were markedly decreased to concentrations which were severalfold lower than the achievable cerebrospinal fluid flucytosine concentration. On the other hand, the addition of flucytosine did not greatly enhance the in vitro activity of fluconazole if the initial fluconazole MIC for the isolate was > or = 8 micrograms/ml. Controlled clinical studies are warranted to further elucidate the potential utility of fluconazole-flucytosine combination therapy.
Similar articles
-
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.Diagn Microbiol Infect Dis. 1998 Nov;32(3):191-9. doi: 10.1016/s0732-8893(98)00095-9. Diagn Microbiol Infect Dis. 1998. PMID: 9884835
-
The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.Mycoses. 2019 Sep;62(9):818-825. doi: 10.1111/myc.12955. Epub 2019 Jun 23. Mycoses. 2019. PMID: 31173410 Free PMC article.
-
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.Antimicrob Agents Chemother. 1997 Feb;41(2):331-6. doi: 10.1128/AAC.41.2.331. Antimicrob Agents Chemother. 1997. PMID: 9021188 Free PMC article.
-
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.Cochrane Database Syst Rev. 2008 Oct 8;(4):CD005647. doi: 10.1002/14651858.CD005647.pub2. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2018 Jul 25;7:CD005647. doi: 10.1002/14651858.CD005647.pub3 PMID: 18843697 Updated. Review.
-
Searching for new antifungals for the treatment of cryptococcosis.Rev Soc Bras Med Trop. 2023 Jul 24;56:e01212023. doi: 10.1590/0037-8682-0121-2023. eCollection 2023. Rev Soc Bras Med Trop. 2023. PMID: 37493736 Free PMC article. Review.
Cited by
-
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.Antimicrob Agents Chemother. 2013 Feb;57(2):796-803. doi: 10.1128/AAC.00980-12. Epub 2012 Nov 26. Antimicrob Agents Chemother. 2013. PMID: 23183435 Free PMC article.
-
Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.Eur J Clin Microbiol Infect Dis. 1997 Nov;16(11):846-8. doi: 10.1007/BF01700417. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9447909
-
In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.Antimicrob Agents Chemother. 2004 Jun;48(6):2007-13. doi: 10.1128/AAC.48.6.2007-2013.2004. Antimicrob Agents Chemother. 2004. PMID: 15155192 Free PMC article.
-
Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays.Infect Immun. 2013 Jun;81(6):1880-8. doi: 10.1128/IAI.01328-12. Epub 2013 Mar 18. Infect Immun. 2013. PMID: 23509144 Free PMC article.
-
In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.Antimicrob Agents Chemother. 2005 Jul;49(7):2994-6. doi: 10.1128/AAC.49.7.2994-2996.2005. Antimicrob Agents Chemother. 2005. PMID: 15980382 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources